The alternative to ICI is targeted therapy aimed at driver mutations, with BRAF being the most prevalent mutation in cutaneous melanoma and c-KIT being the most prevalent mutation in mucosal melanoma. This evidence concerns the gene KIT and mucosal melanoma.